31 Jan - 14 Feb 2022Rights issue
Time is everything in cancer care. Today it may take several months before clinicians may know if a specific treatment is effective. Our goal is to shorten this time considerably and to enable that every patient gets the appropriate cancer care at the right time.
AroCell AB is a Swedish in vitro diagnostics company focusing on the monitoring of hematological malignancies, breast cancer, and other solid tumors. They are currently involved in the development, manufacture, and sale of products for the measurement of human Thymidine Kinase 1 (TK1) concentration in blood. The company, based in Uppsala, Sweden, is listed on NASDAQ First North Growth Market and owned by more than 2,500 shareholders.
They have a broad and deep patent portfolio relating to antibodies and their use and our proprietary product is AroCell TK 210 ELISA. This CE-marked assay has been designed for simple, robust, and scalable measurement of Thymidine Kinase 1 (TK1) in blood samples. The technology has been assembled in an in vitro diagnostic kit, designed for routine use by clinical laboratories and CROs, and for research carried out by pharmaceutical scientists involved in drug discovery and development in the biotech and pharmaceutical industries.
The offer in summary
Record date: 26 January 2022
Subscription period: 31 January- 14 February 2022
Terms: Shareholders as of the record date of January 26, 2022 will receive one (1) subscription right per share held. One (1) subscription right is required to subscribe for one (1) new share.
Price: 0.75 SEK
Trading with warrants: Until 9 February 2022
The offer:: The rights issue of a maximum of 114 613 113 shares corresponds to, at fully subscribed, a total issue volume of approx MSEK 85.9
Marketplace: First North Stockholm